Payment overview · 2025
General Payments
$284.78
15 reported records · 8 companies
Healthcare provider profile · identity verified
Michael Mattingly, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MANSFIELD, TX · NPI 1639533730
Verified facts
What the public records show
CMS Open Payments records show Michael Mattingly, M.D. received $284.78 in general payments during 2025 across 15 reported records.
GlaxoSmithKline, LLC. accounted for 26.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $74.03 | 26.0% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $54.10 | 19.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.22 | 12.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.10 | 12.0% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $33.16 | 11.6% | 1 | 2025 |
| BIOTRONIK NRO, Inc. | Unresolved — no canonical attribution shown | $21.16 | 7.4% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $16.55 | 5.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.46 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $284.78 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $55.27 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $54.10 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.22 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.22 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $34.10 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $33.16 | 1 | 2025 |
Source payment records
|
|||||
| Prospera Normalized: prospera |
Device | BIOTRONIK NRO, Inc. | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 733 | 215 |
| Levothyroxine Sodium | Levothyroxine Sodium | 429 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 374 | 117 |
| Losartan Potassium | Losartan Potassium | 308 | 91 |
| Metformin Hcl | Metformin Hcl | 259 | 76 |
| Lisinopril | Lisinopril | 258 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 201 | 74 |
| Trazodone Hcl | Trazodone Hcl | 197 | 69 |
| Duloxetine Hcl | Duloxetine Hcl | 187 | 48 |
| Omeprazole | Omeprazole | 187 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 182 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 169 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 161 | 51 |
| Gabapentin | Gabapentin | 152 | 55 |
| Montelukast Sodium | Montelukast Sodium | 147 | 47 |
| Glimepiride | Glimepiride | 134 | 41 |
| Alprazolam | Alprazolam | 123 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 123 | 31 |
| Carvedilol | Carvedilol | 120 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 55 |
| Simvastatin | Simvastatin | 117 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 108 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 31 |
| Alendronate Sodium | Alendronate Sodium | 100 | 27 |
| Potassium Chloride | Potassium Chloride | 98 | 32 |
| Tramadol Hcl | Tramadol Hcl | 98 | 33 |
| Jardiance | Empagliflozin | 95 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 25 |
| Furosemide | Furosemide | 81 | 34 |
| Meloxicam | Meloxicam | 80 | 36 |
| Sertraline Hcl | Sertraline Hcl | 80 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 33 |
| Allopurinol | Allopurinol | 77 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 72 | 28 |
| Bupropion Xl | Bupropion Hcl | 71 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 19 |
| Clonazepam | Clonazepam | 65 | 11 |
| Ezetimibe | Ezetimibe | 64 | 18 |
| Eliquis | Apixaban | 62 | 18 |
| Metformin Hcl Er | Metformin Hcl | 59 | 15 |
| Azithromycin | Azithromycin | 57 | 49 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 15 |
| Lovastatin | Lovastatin | 55 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 16 |
| Buspirone Hcl | Buspirone Hcl | 51 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 24 |
| Atenolol | Atenolol | 48 | 16 |
| Nifedipine Er | Nifedipine | 47 | 15 |
| Ozempic | Semaglutide | 47 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 15 |
| Methocarbamol | Methocarbamol | 44 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 43 | 16 |
| Ondansetron Odt | Ondansetron | 43 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | 13 |
| Mupirocin | Mupirocin | 41 | 32 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 37 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 12 |
| Temazepam | Temazepam | 36 | suppressed |
| Methylprednisolone | Methylprednisolone | 34 | 31 |
| Valsartan | Valsartan | 34 | 12 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 33 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 26 |
| Prednisone | Prednisone | 33 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 27 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | 11 |
| Trulicity | Dulaglutide | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | 11 |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Cephalexin | Cephalexin | 27 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | 11 |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 14 |
| Diazepam | Diazepam | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 18 |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 15 | suppressed |
| Fluconazole | Fluconazole | 14 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $284.78 · 15 records | GlaxoSmithKline, LLC. | BREZTRI, Cologuard Collection Kit, INSPIRE, MOUNJARO, Paradise Ultrasound Renal Denervation System, Prospera, REXULTI, SHINGRIX, TRELEGY ELLIPTA, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error